100% Heparin-Free
Eliminates exposure to HIT/HITTS risk and systemic anticoagulation concerns.
For Healthcare Professionals
Elevating Vascular Access Safety with Precision Citrate Solutions
Trusted heparin-free catheter locking for dialysis and intensive care, delivered in CitraFlow 4%, 30%, and 46.7% pre-filled syringes engineered for patency, infection control, and clinical confidence.
- 87%
- Reduction in bacteremia vs heparin in cited evidence
- 100%
- Heparin-free to avoid HIT/HITTS exposure
- ISO 13485
- Manufactured under quality-certified processes
Biofilm Disruption
High-concentration citrate destabilizes bacterial matrices and helps inhibit coaggregation.
Zero-Reflux Design
Precision syringes are designed to prevent reflux, clotting, and inconsistent locking volumes.
Sterile Field Ready
Terminally sterilized packaging supports immediate use in high-acuity clinical settings.
Product Portfolio
Choose the lock strategy that matches catheter risk profile and workflow
Flushing and Locking
CitraFlow 4% SF
For vascular access device flushing and locking, with citrate-based anti-coagulant support for routine access maintenance.
- Anti-coagulant
- Reduction of biofilm
- No bacterial growth positioning
Locking
CitraFlow 30% SF
For vascular access device locking where anti-coagulant, biofilm reduction, and anti-microbial properties are priorities.
- Anti-coagulant
- Reduction of biofilm
- Anti-microbial
Concentrated Locking
CitraFlow 46.7% SF
For vascular access device locking with a higher sodium citrate concentration in the CitraFlow prefilled syringe family.
- Anti-coagulant
- Reduction of biofilm
- Anti-microbial
Clinical Evidence
Evidence-based outcomes for access safety, patency, and infection prevention
Backed by multicenter trials including the referenced Weijmer study, CitraFlow positions citrate locking as a safety-forward alternative to conventional heparin protocols.
87%
Reduction in bacteremia compared with heparin in cited trial data.
Reduced Bleeding
Meta-analysis findings in the brief cite a 52% reduction in major bleeding events after switching to citrate locks.
Superior Biofilm Control
Higher citrate concentrations are presented as more effective against sessile bacteria than lower-concentration heparin mixtures.
Manufacturing Compliance
Manufactured by MedXL under ISO 13485-certified quality systems and positioned for Australian ARTG distribution disclosure.
Clinician's Corner
Give procurement and frontline teams the materials they need in one place
Clinical Fact Sheet
Provide a PDF summary covering indications, evidence highlights, formats, and administration notes.
Request from distributorProduct Photography
Reserve this space for MedXL syringe imagery, emphasizing cap color differentiation for 4% and 30% variants.
Blue cap: 4% | Yellow/Orange cap: 30%Implementation Support
Use this section for onboarding packs, nursing in-service bookings, and procurement specification sheets.
Mobile-ready for tablet review on the wardContact & Quote Request
Partner with us for better patient outcomes
Collect interest from nephrology, ICU, oncology, and procurement teams with a clinically focused intake form.